ESMO Symposium on Signalling Pathways in Cancer 2018

23 - 24 Mar 2018

Barcelona, Spain

Signalling Pathways 2018 - square
Signalling Pathways 2018 - square

ESMO Symposium on Signalling Pathways in Cancer, in partnership with the European Association for Cancer Research (EACR), will focus on Cyclin-dependent kinases (CDKs). Presentations and webcasts from the ESMO Symposium on Signalling Pathways in Cancer 2018 are available here to ESMO members.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings

Video report from Violetta Serra on Understanding the Mecanism of Resistance to CDK4/6 Inhibitors

Most of oestrogen receptor positive metastatic breast cancer patients are receiving CDK4/6 inhibitors, now approved for first-line treatment. Violetta Serra explains that the challenge is now to identify resistance to these drugs in order to establish potential second line treatments.

Hide
Filter by:

There are 26 resources available

Panel Discussion

Presenter: Josep Tabernero

Session: Role of CDK 4-6 inhibitors across solid tumors

Resources:

Presentation

Webcast

Palbociclib

Presenter: Javier Cortes

Session: CDK4 and CDK6 inhibitors in breast cancer

Resources:

Presentation

Webcast

Ribociclib

Presenter: Fabrice André

Session: CDK4 and CDK6 inhibitors in breast cancer

Resources:

Presentation

Webcast

Abemaciclib

Presenter: Antonio Llombart-Cussac

Session: CDK4 and CDK6 inhibitors in breast cancer

Resources:

Presentation

Webcast

Are all CDK 4-6 created equal?

Presenter: Giuseppe Curigliano

Session: CDK4 and CDK6 inhibitors in breast cancer

Resources:

Presentation

Webcast

Dinaciclib

Presenter: Cristina Saura

Session: The disappointing results of initial CDKI and their role in other disease

Resources:

Presentation

Roscovitine

Presenter: Laurent Meijer

Session: The disappointing results of initial CDKI and their role in other disease

Resources:

Presentation

Webcast

CDKi in non-malignant diseases

Presenter: Laurent Meijer

Session: The disappointing results of initial CDKI and their role in other disease

Resources:

Presentation

Webcast

PIK3

Presenter: Violeta Serra

Session: Interaction between CDKs, CDKI and other targets

Resources:

Presentation

Synthetic lethality

Presenter: Rene Bernards

Session: Interaction between CDKs, CDKI and other targets

Resources:

Presentation

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings